Cargando…

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

BACKGROUND: The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from three risedronate Japanese phase III trials. The clinical effect of risedronate therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigematsu, Takashi, Muraoka, Ryoichi, Sugimoto, Toshitsugu, Nishizawa, Yoshiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311729/ https://www.ncbi.nlm.nih.gov/pubmed/28201994 http://dx.doi.org/10.1186/s12882-017-0478-9

Ejemplares similares

Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan
por: Inoue, Daisuke, et al.
Publicado: (2015)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials
por: Mawatari, T., et al.
Publicado: (2016)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial
por: Mawatari, Taro, et al.
Publicado: (2020)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

Efficacy of topical risedronate and risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis
por: Peralta, Ma. Florencia, et al.
Publicado: (2021)

Risedronate inhibits human osteosarcoma cell invasion
por: Xin, Zeng Feng, et al.
Publicado: (2009)

Crystallization Products of Risedronate with Carbohydrates and Their Substituted Derivatives (†)
por: Kos, Jiri, et al.
Publicado: (2011)

Preparation of Risedronate Nanoparticles by Solvent Evaporation Technique
por: Vaculikova, Eliska, et al.
Publicado: (2014)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Risedronate-loaded aerogel scaffolds for bone regeneration
por: El-Wakil, Nahla, et al.
Publicado: (2022)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
por: Kleinermans, Diane, et al.
Publicado: (2022)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
por: Yang, Chengzhi, et al.
Publicado: (2020)

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement
por: Saifi, Zoya, et al.
Publicado: (2023)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2021)

Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats
por: Asada, Yohei, et al.
Publicado: (2019)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
por: McClung, M. R., et al.
Publicado: (2012)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis
por: Calabria, S, et al.
Publicado: (2016)

Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate
por: Matsumoto, Y., et al.
Publicado: (2009)

The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation
por: Valenti, Maria Teresa, et al.
Publicado: (2010)

Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis
por: Permuy, María, et al.
Publicado: (2014)

Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole
por: Monda, Vincenzo, et al.
Publicado: (2017)

SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta
por: Nguyen, Antoine T, et al.
Publicado: (2020)

Histomorphometric Effects of 2% Risedronate Gel on Calvarial Bone Defects in Rabbits
por: Aghayan, Shabnam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9c1jmc5nf1914a7emp6la53nnu